You are leaving this website

You are now leaving the Galafold.com/hcp website. The site you are going to may not be owned or maintained by Amicus Therapeutics. Amicus Therapeutics is not responsible for the information contained on third-party sites.

You are leaving this website

You are now leaving the Galafold.com/hcp website. The site you are going to may not be owned or maintained by Amicus Therapeutics. Amicus Therapeutics is not responsible for the information contained on third-party sites.

You are leaving this website

You are now leaving the Galafold.com/hcp website. The site you are going to may not be owned or maintained by Amicus Therapeutics. Amicus Therapeutics is not responsible for the information contained on third-party sites.

You are leaving this website

You are now leaving the Galafold.com/hcp website. The site you are going to may not be owned or maintained by Amicus Therapeutics. Amicus Therapeutics is not responsible for the information contained on third-party sites.

You are leaving this website

You are now leaving the Galafold.com/hcp website. The site you are going to may not be owned or maintained by Amicus Therapeutics. Amicus Therapeutics is not responsible for the information contained on third-party sites.

You are leaving this website

You are now leaving the Galafold.com/hcp website. The site you are going to may not be owned or maintained by Amicus Therapeutics. Amicus Therapeutics is not responsible for the information contained on third-party sites.

You are leaving this website

You are now leaving the Galafold.com/hcp website. The site you are going to may not be owned or maintained by Amicus Therapeutics. Amicus Therapeutics is not responsible for the information contained on third-party sites.

You are leaving this website

You are now leaving the Galafold.com/hcp website. The site you are going to may not be owned or maintained by Amicus Therapeutics. Amicus Therapeutics is not responsible for the information contained on third-party sites.

You are leaving this website

You are now leaving the Galafold.com/hcp website. The site you are going to may not be owned or maintained by Amicus Therapeutics. Amicus Therapeutics is not responsible for the information contained on third-party sites.

You are leaving this website

You are now leaving the Galafold.com/hcp website. The site you are going to may not be owned or maintained by Amicus Therapeutics. Amicus Therapeutics is not responsible for the information contained on third-party sites.

You are leaving this website

You are now leaving the Galafold.com/hcp website. The site you are going to may not be owned or maintained by Amicus Therapeutics. Amicus Therapeutics is not responsible for the information contained on third-party sites.

You are leaving this website

You are now leaving the Galafold.com/hcp website. The site you are going to may not be owned or maintained by Amicus Therapeutics. Amicus Therapeutics is not responsible for the information contained on third-party sites.

You are leaving this website

You are now leaving the Galafold.com/hcp website. The site you are going to may not be owned or maintained by Amicus Therapeutics. Amicus Therapeutics is not responsible for the information contained on third-party sites.

You are leaving this website

You are now leaving the Galafold.com/hcp website. The site you are going to may not be owned or maintained by Amicus Therapeutics. Amicus Therapeutics is not responsible for the information contained on third-party sites.

Request a visit from your Galafold® (migalastat) Rare Disease Specialist

Find out if Galafold may be an appropriate treatment for your patients with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene (GLA) variant. Once you submit your request, a representative will contact you.

Please fill in all fields below and submit your request.

All fields required.

How would you like to be contacted?
Only One Field Required.

Which of the following would you like more information on? (Check all that apply.)

Thank you for your request!
Oops! Something went wrong while submitting the form.

Important safety information AND INDICATION

IMPORTANT SAFETY INFORMATION

ADVERSE REACTIONS

The most common adverse drug reactions reported with Galafold (≥10 %) are headache, nasopharyngitis, urinary tract infection, nausea, and pyrexia.

USE IN SPECIFIC POPULATIONS

There is insufficient clinical data on Galafold use in pregnant women to inform a drug associated risk for major birth defects and miscarriage. Advise women of the potential risk to a fetus.

It is not known if Galafold is present in human milk. Therefore, the developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for Galafold and any potential adverse effects on the breastfed child from Galafold or from the underlying maternal condition.

Galafold is not recommended for use in patients with severe renal impairment or end-stage renal disease requiring dialysis.

The safety and effectiveness of Galafold have not been established in pediatric patients.

To report Suspected Adverse Reactions, contact Amicus Therapeutics at 1-877-4-AMICUS or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

INDICATIONS AND USAGE

Galafold is indicated for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene (GLA) variant based on in vitro assay data.

This indication is approved under accelerated approval based on reduction in kidney interstitial capillary cell globotriaosylceramide (KIC GL-3) substrate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.

Please see accompanying Full Prescribing Information.

Access resources and support
for you and your office

Not an actual patient with Fabry disease.

Access resources and support for you and your office

Learn about an option for genetic testing for Fabry disease

Learn about a no-charge option for genetic testing to help you confirm a diagnosis and determine your patient’s specific GLA variant.

LEARN MORE

Help your patients get support with Amicus Assist®

AMICUS ASSIST is a program designed to provide assistance and support to help eligible patients with Fabry disease and an amenable GLA variant obtain access to Galafold.*

*Patients must be prescribed Galafold for an approved indication to be eligible for support from AMICUS ASSIST.

VISIT NOW

Learn more about Fabry disease at FabryFacts.com

Understand more about the complexities of this disease, including signs, symptoms, how diagnosis can vary between genders, and much more.

VISIT NOW
Check if your patient’s GLA variant is amenable to Galafold
LEARN MORE
Check if your patient’s GLA variant is
amenable to Galafold
LEARN MORE

Test your patients for Fabry disease or determine their specific GLA variant with Amicus-sponsored, no-charge genetic testing

Sponsored, no-charge genetic testing and counseling for patients suspected of having a lysosomal storage disease (LSD) and patients suspected of having a familial cardiomyopathy or arrhythmia.*

Click here to learn more.

*

While third parties and commercial organizations may provide financial support for this program, tests and services are performed by Invitae. Healthcare professionals must confirm that patients meet certain criteria to use the program. Third parties and commercial organizations may receive de-identified patient data from this program, but at no time would they receive patient identifiable information. Third parties and commercial organizations may receive contact information for healthcare professionals who use this program. Genetic testing and counseling are available in the US and Canada. Healthcare professionals and patients who participate in this program have no obligation to recommend, purchase, order, prescribe, promote, administer, use, or support any other products or services from Invitae or from third parties or commercial organizations.

Detect lysosomal storage diseases (LSDs)
The Invitae Detect LSDs program offers sponsored, no-charge genetic testing and counseling to diagnose LSDs, bringing patients closer to an accurate diagnosis and appropriate clinical management. To order a test, please visit www.invitae.com/detectLSDs.

Detect a familial cardiomyopathy or arrhythmia
The Invitae Detect Cardiomyopathy and Arrhythmia program offers no-charge genetic testing and counseling for people suspected of having a familial cardiomyopathy or arrhythmia. To order a test, please visit www.invitae.com/detect-cardiomyopathy-arrhythmia.

Request a kit
For more information regarding test kits, please visit www.invitae.com/request-a-kit.

Specimen and shipping requirements
For information regarding specimen and shipping requirements, please visit www.invitae.com/en/specimen-requirements.

Additional details about the program, as well as terms and conditions, are available for you and your patients at www.invitae.com.

Downloadable resources for your practice

Galafold Patient Referral Form

This form serves a dual purpose: as a prescription for Galafold and as a way for patients to register for AMICUS ASSIST.

DOWNLOAD NOW

Volume of Distribution

Learn more about Galafold and its volume of distribution.

DOWNLOAD NOW

Galafold® MyDay App Postcard

Help your patients establish a dosing regimen with Galafold by using the Galafold® MyDay app. Download this postcard to have on hand to give to your Galafold patients.

DOWNLOAD NOW

A Quick Guide to Galafold

This flashcard has key, quick-hitting information about Galafold, dosing and administration, and patient support.

DOWNLOAD NOW

Renal Impact of Fabry Disease

Discover more about the impact Fabry disease has on the kidneys and other organ systems, and how treatment with Galafold may help.

DOWNLOAD NOW

INDICATIONS AND USAGE

Galafold® (migalastat) is indicated for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene (GLA) variant based on in vitro assay data.

This indication is approved under accelerated approval based on reduction in kidney interstitial capillary cell globotriaosylceramide (KIC GL-3) substrate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.

Patient advocacy organizations

Help your patients with Fabry disease keep moving forward with Galafold